StockData
Starling Oncology, Inc. logo

Starling Oncology, Inc. (STLN) stock

STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/30
$3.50−0.25 (-6.67%)

Close on Nov 13, 2026Market cap $356.71MP/E –Yield –

Starling Oncology profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Starling Oncology's profit margin for the twelve months ending Sep 30, 2026 was -5.7%. For fiscal 2025 it was -12.1%, against -16.4% the year before. The highest annual figure on record is 0.1% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-12.1%+4.4
FY2024Dec 31, 2024-16.4%+9.2
FY2023Dec 31, 2023-25.6%−25.7
FY2022Dec 31, 20220.1%+5.4
FY2021Dec 31, 2021-5.4%+2.3
FY2020Dec 31, 2020-7.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-9.3%+2.8
Q2 FY2026Jun 30, 2026-6.1%+8.1
Q1 FY2026Mar 31, 2026-1.7%+17.1
Q4 FY2025Dec 31, 2025-5.3%+7.9
Q3 FY2025Sep 30, 2025-12.1%+4.0
Q2 FY2025Jun 30, 2025-14.2%+1.5
Q1 FY2025Mar 31, 2025-18.8%+2.3
Q4 FY2024Dec 31, 2024-13.1%+8.7
Q3 FY2024Sep 30, 2024-16.1%+5.1
Q2 FY2024Jun 30, 2024-15.7%+5.4
Q1 FY2024Mar 31, 2024-21.0%+18.4
Q4 FY2023Dec 31, 2023-21.9%−6.5
Q3 FY2023Sep 30, 2023-21.2%−17.1
Q2 FY2023Jun 30, 2023-21.1%−12.1
Q1 FY2023Mar 31, 2023-39.4%−74.3
Q4 FY2022Dec 31, 2022-15.4%+4.0
Q3 FY2022Sep 30, 2022-4.1%+1.6
Q2 FY2022Jun 30, 2022-9.0%−15.4
Q1 FY2022Mar 31, 202235.0%+37.0
Q4 FY2021Dec 31, 2021-19.4%–
Q3 FY2021Sep 30, 2021-5.7%–
Q2 FY2021Jun 30, 20216.4%–
Q1 FY2021Mar 31, 2021-2.1%–

More Starling Oncology figures

See a number that looks wrong?